Clinical Study

Multiple Coronary Artery Thrombosis in 5,10-Methylenetetrahydrofolate Reductase Gene Mutation

Alfonso Campanile, Fabiola B. Sozzi, and Gian Battista Danzi

Department of Cardiology, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Via F. Sforza, 35 20122 Milano, Italy

Correspondence should be addressed to Alfonso Campanile, alfonsocampanile@hotmail.it

Received 19 April 2011; Revised 10 July 2011; Accepted 14 July 2011

Academic Editor: Robin Nijveldt

Copyright © 2011 Alfonso Campanile et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 42-year-old man presented at our attention with chest pain. His cardiac risk factors were a smoking habit and family history of coronary artery disease. At the ECG, a mild ST-segment elevation in the inferior leads was shown. A normal left ventricular function was demonstrated at the echocardiography. An emergency coronary angiography was performed, and an extensive thrombosis of the right coronary artery and midleft anterior descending coronary artery was visualized. A primary angioplasty with thrombus aspiration and direct stenting of both sites followed. Biochemical analysis revealed a high plasma homocysteine level with a homozygotic anomaly of the 5,10-methylenetetrahydrofolate reductase. Currently, a nine-month followup negative for cardiac events is recorded.

1. Introduction

Simultaneous thrombosis of multiple epicardial coronary arteries is an uncommon angiographic finding in ST-segment elevation myocardial infarction. It is related to several factors such as diffuse vessel spasm, state of hypercoagulability, and a decreased coronary blood pressure [1].

Hyperhomocysteinemia is a risk factor of coronary artery disease associated to arterial thrombosis. It is characterized by an abnormally high concentration of homocysteine (a sulfurated amino acid produced through the methionine metabolism).

This paper describes a case of ST-segment elevation myocardial infarction secondary to thrombosis of two coronary arteries in a patient affected by intermediate hyperhomocysteinemia gene mutation related.

2. Case Presentation

A 42-year-old male presented at the emergency room of the Hospital Policlinico, Milan, Italy with chest pain. He did not have any medical disease including hypertension, diabetes mellitus, dyslipidemia, and denied cocaine abuse. He was a smoker with familial premature coronary artery disease history; his body mass index was 22.6. The vital signs were normal (blood pressure: 130/80 mmHg, heart rate: 73 bpm, and oxygen saturation: 100%), and physical examination revealed no abnormalities. A 2 mm ST-segment elevation in the inferior leads was documented at the electrocardiogram. After an initial medical treatment with unfractionated heparin, acetyl salicylic acid, and clopidogrel, the patient was transported to the catheterization laboratory. The coronary angiogram revealed a normal left main and circumflex artery and two luminal irregularities of right coronary artery (RCA) and left anterior descending artery (LAD) complicated by wide coronary thrombosis (Figures 1(a) and 1(c)). Then, a glycoprotein IIb/IIIa inhibitor was administered according to standard protocol and thrombus aspiration, followed by direct stent implantation in the mid-RCA and mid-LAD (resp., with two and one bare metal stent), which were successfully performed (Figures 1(b) and 1(d)). A transthoracic echocardiogram showed a mildly reduced left ventricular function (ejection fraction 53%) with a normal right ventricular size and function.

A moderately high plasma homocysteine level (>50 µmol/L) with normal serum vitamin B12 and folate levels were found at the biochemical analysis, together with normal renal and serum lipid profiles. A mild increase of
troponin T (peak 0.31 ng/mL, normal range: 0.00–0.03) was detected. The thrombophilia screening findings are shown in Table 1. The genetic testing for the methylenetetrahydrofolate reductase showed the presence of C677T mutation in homozygosis. Therefore, oral folic acid supplementation (5 mg/die) was initiated. Currently, a nine-month followup negative for cardiac events is recorded; the plasma homocysteine level remained at the upper normal limit after methionine treatment.

3. Discussion and Conclusion

Simultaneous multivessel thrombosis in the setting of acute myocardial infarction is a rare entity. A case of acute thrombosis of two simultaneous coronary arteries in a young adult with familial hyperhomocysteinemia is described.

Numerous studies have indicated that an increased plasma homocysteine level is a risk factor for occlusive arterial or venous disease [2–4].

Hyperhomocysteinemia usually occurs in people with at least one defective gene that affects the breakdown of homocysteine. There are two common defective genes in the population. The first one is related to the enzyme methylene-tetrahydrofolate reductase, the second to the methionine-synthetase. Other causes of hyperhomocysteinemia are represented by deficiency of vitamin B, impaired renal function, and negative lifestyle factors (smoking habit, coffee abuse, and sedentary lifestyle). [5, 6] Hyperhomocysteinemia is

| Tests                                | Results (normal range) |
|--------------------------------------|------------------------|
| Prothrombin time                      | 10.80 seconds (8.9–11.7) |
| International normalized ratio (INR) | 0.96 (0.90–1.14)       |
| Activated partial thromboplastin time | 25.7 (24.5–35.2)       |
| Homocysteine (Hcy)                   | >50 µmol/L (4.00–15.40) |
| Protein C activity (%)               | 122% (72–160)          |
| Protein S activity (%)               | 152% (79–183)          |
| Antithrombin III activity            | 108.0% (82.0–112.0)    |
| Factor V Leiden mutation             | Negative               |
| Prothrombin gene mutation            | Negative               |
| Phospholipid (cardiolipin) AB IgG    | 1.8 U/mL GPL (0–10)    |
| Phospholipid (cardiolipin) AB IgM    | 0.0 U/mL MPL (0–10)    |
| Lupus anticoagulant                  | Absent                 |
classified as mild-moderate (15–30 µmol per liter), inter-
mediate (>31–100 µmol per liter), and severe (>100 µmol per
liter) [7].

Subjects with moderate hyperhomocysteinaemia are
characterized by a prothrombotic, and dysfibrinolytic state
and homocysteine level is an independent predictor of
thrombotic events. [8] The oxidative injury of endothelium
in homocysteinaemia, combined with the lack of vascular-
protective effects of nitric oxide, predisposes to thrombotic
events [8]. It is now widely accepted that increased plasma
homocysteine is associated with increased cardiovascular
risk independently of other atherosclerosis risk factors. [9]
However, it is still unclear whether plasma homocysteine can
be approached as a modifiable risk factor for atherosclerosis
[10]. Our patient showed elevated homocysteine levels asso-
ciated with homozygosity for the C677T gene mutation of
methylenetetrahydrofolate reductase. A significantly higher
frequency of this genetic condition was found in patients
with early coronary artery disease onset (age <45 years) [11].

Politi et al. presented a case of a 35-year-old patient, with
extensive anterior AMI and multiple thrombotic occlusion
(in the distal LAD, diagonal branches, and obtuse marginal
branch). Also this case was associated to elevated homocys-
eteine (in the distal LAD, diagonal branches, and obtuse marginal
extensive anterior AMI and multiple thrombotic occlusion

No routine screening for elevated homocysteine and
treatment is currently recommended except in patients who
have premature atherosclerosis [13].

Further investigation on hyperhomocysteinaemia and
coronary heart disease is needed.

Conflict of Interests
The authors declare that they have no conflict of interests.

References

[1] C. M. Tu, C. H. Hsueg, K. M. Chu, S. M. Cheng, and T. P. Tsao,
"Simultaneous thromboses of double coronary arteries in a
young male with antithrombin III deficiency," The American
Journal of Emergency Medicine, vol. 27, no. 9, pp. e1163–e1166,
2009.

[2] M. J. Stampfer, M. R. Malinow, W. C. Willett et al., "A prospective
study of plasma homocyst(e)ine and risk of myocardial
infarction in US physicians," The Journal of the American
Medical Association, vol. 268, no. 7, pp. 877–881, 1992.

[3] M. den Heijer, H. J. Blom, W. B. J. Gerrits et al., "Is hyperho-
cysteinaemia a risk factor for recurrent venous thrombo-
sis?" The Lancet, vol. 345, no. 8954, pp. 882–885, 1995.

[4] O. Nygard, J. E. Nordrehaug, H. Refsum, P. M. Ueland, M.
Farstad, and S. E. Vollset, "Plasma homocysteine levels and
mortality in patients with coronary artery disease," The New
England Journal of Medicine, vol. 337, no. 4, pp. 230–236, 1997.

[5] O. Nygard, H. Refsum, P. M. Ueland, and S. E. Vollset, "Major
lifestyle determinants of plasma total homocysteine distri-
bution: the Hordaland homocysteine study," The American
Journal of Clinical Nutrition, vol. 67, no. 2, pp. 263–270, 1998.

[6] E. Nurk, G. S. Tell, S. E. Vollset et al., "Changes in lifestyle
and plasma total homocysteine: the Hordaland homocysteine
study," The American Journal of Clinical Nutrition, vol. 79, no.
5, pp. 812–819, 2004.

[7] H. Refsum, A. D. Smith, P. M. Ueland et al., "Facts and rec-
ommendations about total homocysteine determinations: an
expert opinion," Clinical Chemistry, vol. 50, no. 1, pp. 3–32,
2004.

[8] T. Bienvenu, A. Ankri, B. Chadefaux, G. Montalescot, and P.
Kamoun, "Elevated total plasma homocysteine, a risk factor
for thrombosis. Relation to coagulation and fibrinolytic pa-
rameters," Thrombosis Research, vol. 70, no. 2, pp. 123–129,
1993.

[9] W. G. Christen, U. A. Ajani, R. J. Glynn, and C. H. Hen-
nekens, "Blood levels of homocysteine and increased risks of
cardiovascular disease: causal or casual?" Archives of Internal
Medicine, vol. 160, no. 4, pp. 422–434, 2000.

[10] C. Antoniades, A. S. Antonopoulos, D. Trousoulis, K. Marinou,
and C. Stefanadis, "Homocysteine and coronary atheroscle-
rosis: from folate fortification to the recent clinical trials," Eu-
erpean Heart Journal, vol. 30, no. 1, pp. 6–15, 2009.

[11] M. Klerk, P. Verhoef, R. Clarke, H. J. Blom, F. J. Kok, and
E. G. Schouten, "MTHFR 677C→T polymorphism and risk
of coronary heart disease: a meta-analysis," The Journal of the
American Medical Association, vol. 288, no. 16, pp. 2023–2031,
2002.

[12] L. Politi, D. E. Monopoli, and M. G. Modena, "ST-segment
elevation myocardial infarction with concomitant multiple
coronary arteries thromboses in a young patient with hyper-
homocysteinaemia," Heart, vol. 94, no. 9, p. 1180, 2008.

[13] M. N. Di Minno, E. Tremoli, A. Coppola, R. Lupoli, and G. Di
Minno, "Homocysteine and arterial thrombosis: challenge and
opportunity," Thrombosis and Haemostasis, vol. 103, no. 5, pp.
942–961, 2010.